Skip to main content

Table 3 Prediction of baseline factor for mortality in patients with ILD and NSCLC assessed using the Cox proportional-hazards model

From: Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease

Variable

Univariate analysis

Multivariate analysis

HR

95% CI

P Value

HR

95% CI

P Value

Age

1.006

0.971–1.043

0.736

   

Male

3.426

0.832–14.111

0.088

   

Ever-smoker

1.139

0.486–2.671

0.765

   

IPF

(vs. non-IPF ILD)

0.963

0.563–1.649

0.892

   

SqCC (vs. ADC)

1.039

0.613–1.759

0.888

   

PFT

 FVC (predicted), %

0.983

0.968–0.998

0.023

0.992

0.974–1.011

0.411

 FEV1 (predicted), %

0.989

0.972–1.006

0.189

   

 TLC (predicted), %

0.961

0.934–0.988

0.005

   

 DLco (predicted), %

0.986

0.973-1.000

0.051

   

KL-6 ≥ 1000 U/mL

2.554

1.378–4.734

0.003

1.970

1.026–3.783

0.042

Lung cancer stage

 Stage I (ref)

      

 Stage II

4.476

1.778–11.271

0.001

3.876

1.187–12.660

0.025

 Stage III

3.722

1.612–8.594

0.002

5.092

1.801–14.401

0.002

 Stage IV

8.717

3.630-20.936

< 0.001

5.626

1.889–16.757

0.002

  1. HR, hazard ratio; CI, confidence interval; SqCC, squamous cell carcinoma; ADC, adenocarcinoma; PFT, pulmonary function test; TLC, total lung capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLco, diffusing capacity for carbon monoxide; IPF, idiopathic pulmonary fibrosis; ILD, interstitial lung disease; KL-6, Krebs von den Lungen-6; IS, immunosuppressant; CCRT, concurrent chemoradiation therapy
  2. TLC was not included in the multivariate analysis owing to its high correlation with FVC (r = 0.853, p < 0.001)
  3. Bold values denote statistical significance at the p < 0.05 level
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us